Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs. 2013

Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Educational Ministry of China), School of Pharmaceutical Sciences, Shandong University, No. 44 Wenhuaxi Road, Jinan, 250012, China.

On the basis of structural features, binding mode, and structure-activity relationship studies of two pyrimidine-derived non-nucleoside reverse-transcriptase inhibitors, DABOs, and diaryl pyrimidines, a novel class of 1,2,6-thiadiazine-1,1-dione derivatives were rationally designed using the strategies of bioisosterism and molecular hybridization, synthesized, and evaluated for their anti-HIV activity in MT4 cell cultures. Three compounds were found to have moderate activity against HIV-1 replication with EC50 values ranging from 23 to 32 μm. To further confirm the binding target, compound IIg was selected to conduct an HIV-1 reverse-transcriptase inhibitory assay. In addition, preliminary structure-activity relationship analysis among the newly synthesized compounds was discussed, and the binding mode of the active compound IIg was rationalized by molecular docking and physicochemical studies.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013829 Thiadiazines
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
July 2015, Chemical biology & drug design,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
November 1986, Il Farmaco; edizione scientifica,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
January 2023, European journal of medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
April 2013, Bioorganic & medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
April 1972, Journal of medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
August 1992, Archiv der Pharmazie,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
November 2017, European journal of medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
June 2021, Bioorganic & medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
November 2013, Bioorganic & medicinal chemistry,
Ye Tian, and Diwakar Rai, and Peng Zhan, and Christophe Pannecouque, and Jan Balzarini, and Erik De Clercq, and Huiqing Liu, and Xinyong Liu
December 2019, BMC chemistry,
Copied contents to your clipboard!